In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
|Podcasts|March 7, 2023
Treat Disease, Not the Symptoms
Author(s)Lisa Henderson, Andy Studna, Senior Editor
In this podcast, Ira C. Spector, PhD, MBA, CEO and Co-Founder, SFA Therapeutics, discusses how his career journey has epitomized the ability to solve problems, which is essentially the role of drug development. It has also led to the formation and strategic approach to his company’s early-stage clinical trials for using the microbiome to address chronic inflammatory diseases.
Related to this article
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy.
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck.
Trending on Applied Clinical Trials Online
1
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
2
Mixed Outsourcing Models Are Spreading. Is Sponsor Oversight Keeping Up?
3
FDA Seeks Public Input on Early-Phase Clinical Trial Design for Ibogaine
4
Hierarchical Endpoints in Cardiology: How Much Treatment Benefit, and From Where
5